Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Rajkumar

Showing results (321-330 of 773) with videos related to

Pageof 78
Sort By:
Seminars in Oncology|April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaMorie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
Blood|July 16, 2005
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myelomaPaul Gerard Guy Richardson, Bart Barlogie, James Berenson, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 28, 2004
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosisAngela Dispenzieri, Martha Q Lacy, S Vincent Rajkumar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 13, 2006
Natural history of thromboembolism in AL amyloidosisChristine S Halligan, Martha Q Lacy, S Vincent Rajkumar, et al.
Clinical Chemistry|August 29, 2024
Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS ProgressionQian Wang, Benjamin D Andress, Vanessa M K Pazdernik, et al.
Blood Cancer Journal|January 5, 2019
Molecular signatures of multiple myeloma progression through single cell RNA-SeqJin Sung Jang, Ying Li, Amit Kumar Mitra, et al.
Blood|April 28, 2005
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceS Vincent Rajkumar, Robert A Kyle, Terry M Therneau, et al.
Blood|October 16, 2009
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyHuei-Ting Tsai, Neil E Caporaso, Robert A Kyle, et al.
Blood Cancer Journal|December 5, 2024
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health databaseS Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, et al.
Mayo Clinic Proceedings|December 15, 2006
Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assaysJerry A Katzmann, Angela Dispenzieri, Robert A Kyle, et al.
Pageof 78

Showing results (321-330 of 773) with videos related to

Sort By:
Pageof 78
Seminars in Oncology|April 30, 2003
Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaMorie A Gertz, Athanasios Anagnostopoulos, Kenneth Anderson, et al.
Blood|July 16, 2005
Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myelomaPaul Gerard Guy Richardson, Bart Barlogie, James Berenson, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|February 28, 2004
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosisAngela Dispenzieri, Martha Q Lacy, S Vincent Rajkumar, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 13, 2006
Natural history of thromboembolism in AL amyloidosisChristine S Halligan, Martha Q Lacy, S Vincent Rajkumar, et al.
Clinical Chemistry|August 29, 2024
Comparison of 2 Free Light Chain Assays: Performance of the Free Light Chain Ratio as a Risk Factor for MGUS ProgressionQian Wang, Benjamin D Andress, Vanessa M K Pazdernik, et al.
Blood Cancer Journal|January 5, 2019
Molecular signatures of multiple myeloma progression through single cell RNA-SeqJin Sung Jang, Ying Li, Amit Kumar Mitra, et al.
Blood|April 28, 2005
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceS Vincent Rajkumar, Robert A Kyle, Terry M Therneau, et al.
Blood|October 16, 2009
Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective studyHuei-Ting Tsai, Neil E Caporaso, Robert A Kyle, et al.
Blood Cancer Journal|December 5, 2024
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health databaseS Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, et al.
Mayo Clinic Proceedings|December 15, 2006
Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assaysJerry A Katzmann, Angela Dispenzieri, Robert A Kyle, et al.
Pageof 78